Regulatory News
Friday, January 20, 2017
BRIEF-Additional data analyses from phase IIb trial of MIN-101 in schizophrenia underscore benefit in multiple measurements of cognitive function
* Additional data analyses from phase IIb trial of MIN-101
in schizophrenia underscore benefit in multiple measurements of
cognitive function
Source text for Eikon:
Further company coverage:
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment